Suven Life Sciences has been granted a patent from Australia for a drug used in the treatment of disorders associated with neurodegenerative diseases.
The company has been granted one product patent from Australia corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases, it said in a BSE filing.
The patent is valid through 2034.
"We are pleased by the grant of this patent to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally," Suven Life CEO Venkat Jasti said.
Suven Life Sciences' shares were trading 1.20 per cent up at Rs 173 on BSE in the morning trade.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
